Welke patiënten vertonen een respons op de behandeling en welke niet?

We komen er vaak pas door trial & error achter of een behandeling voor iemand werkt. Via moleculaire inzichten en voorspellende algoritmes kunnen we dit in de toekomst mogelijk vooraf al beter inschatten. De tafelgenoten gaan hier in deze podcast over in gesprek.

U kunt de podcast direct via de player hierboven afspelen. Wilt u de aflevering liever opslaan om later te beluisteren, dan kunt u deze hier downloaden.

Download

Referenties

  1. Verstockt et al. TREM-1, the ideal predictive biomarker for endoscopic healing in anti-TNF-treated Crohn’s disease patients? Gut. 2019 Aug;68(8):1531-1533.
  2. Bordon. Cytokines: Oncostatin M – a new target in IBD? Nat Rev Immunol. 2017 May;17(5):280.
  3. https://www.wijbehandelenibd.nl/nieuws/tdm-bij-gebruik-biologicals-op-de-goede-weg-maar-meer-inzichten-broodnodig/
  4. D’Haens et al. Increasing Infliximab Dose Based on Symptoms, Biomarkers, and Serum Drug Concentrations Does Not Increase Clinical, Endoscopic, and Corticosteroid-Free Remission in Patients With Active Luminal Crohn’s Disease. Gastroenterology. 2018 Apr;154(5):1343-1351.e1.
  5. Van de Casteele et al. Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease. Gastroenterology 2015;148:1320-9.e3.
  6. https://www.ecco-ibd.eu/publications/congress-abstract-s/abstracts-2019/item/dop56-dashboard-driven-vs-conventional-dosing-of-infliximab-in-inflammatory-bowel-disease-patients-the-precision-trial.html
  7. Strik et al. Higher anti-TNF serum levels are associated with perianal fistula closure in Crohn’s disease patients. Scand J Gastroenterol. 2019 Apr;54(4):453-458.
  8. Sands et al. Long-term treatment of rectovaginal fistulas in Crohn’s disease: response to infliximab in the ACCENT II Study. Clin Gastroenterol Hepatol. 2004 Oct;2(10):912-20.
  9. Mould et al. Dashboards for Therapeutic Monoclonal Antibodies: Learning and Confirming. AAPS J. 2018 Jun 14;20(4):76.
  10. Löwenberg et al. Vedolizumab Induces Endoscopic and Histologic Remission in Patients With Crohn’s Disease. Gastroenterology. 2019 Jun 5. pii: S0016-5085(19)40985-2.
  11. Papamichael. Therapeutic drug monitoring with biologic agents in immune mediated inflammatory diseases. Expert Rev Clin Immunol. 2019 Aug;15(8):837-848.
  12. Verstockt et al. Ustekinumab Exposure-outcome Analysis in Crohn’s Disease Only in Part Explains Limited Endoscopic Remission Rates. J Crohns Colitis. 2019 Jul 25;13(7):864-872
Meer referenties